Latest Articles
- When should we consider SGLT-2 inhibitors in patients with acute decompensated heart failure?
In the January 2024 issue, the article “When should we consider SGLT-2 inhibitors in patients with acute decompensated heart failure?” by Badwan OZ et al [Cleve Clin J Med 2024; 91(1):47–51. doi:10.3949/ccjm.91a.23034] contained an error in Figure 1.
- Does my patient have testosterone deficiency?
Diagnosis of testosterone deficiency requires the presence of relevant signs or symptoms along with biochemical evidence.
- It’s a new year, looking back and looking forward
Reflections on highlights from 2023 and impending changes in 2024, along with some acknowledgments and farewells.
- Wearable cardiac monitors: Where do we stand?
Wearable monitors perform well as screening tools for atrial fibrillation, but questions remain: Can they help with stroke prevention, what is their role in patients with known atrial fibrillation, and how do we streamline interpretation?
Consumer-grade wearable cardiac monitors: What they do well, and what needs workThe authors review common consumer-grade wearables, including the accuracy of these monitors compared with medical-grade devices, and present an approach to managing rate or rhythm abnormalities identified on at-home monitoring.
- When should we consider SGLT-2 inhibitors in patients with acute decompensated heart failure?
Evidence from clinical trials supports starting these medications as early as possible in patients hospitalized with acute decompensated heart failure who do not have clear contraindications to them.